Optic pathway gliomas in children: Clinical characteristics, treatment, and outcome of 95 patients in a single center over a 31‐year period. Can we avoid radiotherapy?
Pediatric Blood & Cancer · 2024-12 · 71 (12)
DOI: 10.1002/pbc.31337 ↗At a glance
Journal article in Pediatric Blood & Cancer, published online on 2024-09-29. Written by Rejin Kebudi and 3 co-authors. Institution: Division of Pediatric Hematology Oncology, Oncology Institute, Istanbul University, Istanbul, Turkey. Major MEDLINE topics: Optic Nerve Glioma. Cited 7 times so far (Crossref); 34 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Topics: Kinderkrankenpflege
Abstract (original language)
Background
Optic pathway gliomas (OPG) are rare tumors in children. Lesion extent, visual functions, neurofibromatosis 1 (NF1), and age are factors that guide treatment. This study evaluates the clinical characteristics, treatment, and outcome of children and adolescents with OPG treated over a 31‐year period in a single center.
Methods
Ninety‐five patients with OPG diagnosed between January 1990 and December 2021 were retrospectively evaluated. First‐line chemotherapy regimen consisted of vincristine and carboplatinum for 1 year. Radiotherapy was not used as first‐line treatment and tried to be avoided in the ones who progressed after first‐line treatment.
Results
Ninety‐five children (44 male, 51 female) with a median age of 52 (1–216) months were evaluated. Sixty‐three (66.3%) had NF1 and 10 (10,5%) diencephalic syndrome. The most common presenting symptoms were visual abnormalities and/or proptosis, nistagmus, and behavioral changes. Twenty‐one (22.1%) patients with NF1 had stable disease throughout the follow‐up period and received no treatment. Sixty‐three of 74 patients received treatment at diagnosis and 11 due to progression during follow‐up. Only one adolescent received radiotherapy at progression. Patients who progressed, received further line systemic treatment (vinblastine; bevacizumab; vincristine–cisplatinum–etoposide). Ten‐year overall survival in all patients, in patients with NF1, and without NF1 were 97.2%, 98%, and 95.8% ( p > .05), respectively; 10‐year progression‐free survival (PFS) in all patients, in patients with NF1, and without NF1 were 71.6%, 85.7%, and 54.2% ( p = .001), respectively.
Conclusions
In children with symptomatic/progressive OPG, chemotherapy consisting of vincristine–carboplatinum (VC) is effective. Radiotherapy may be avoided, especially in patients with NF1.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Division of Pediatric Hematology Oncology, Oncology Institute, Istanbul University, Istanbul, Turkey.
- Department of Radiation Oncology, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey.
- Department of Ophthalmology, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey.
ORCID profiles: Rejin Kebudi, Ulku Miray Yildirim, Ayça İribaş, Samuray Tuncer
Cite
APA
Kebudi, R., Yildirim, U. M., İribaş, A., & Tuncer, S. (2024). Optic pathway gliomas in children: Clinical characteristics, treatment, and outcome of 95 patients in a single center over a 31‐year period. Can we avoid radiotherapy?. Pediatric Blood & Cancer, 71(12). https://doi.org/10.1002/pbc.31337
Vancouver
Kebudi R, Yildirim UM, İribaş A, Tuncer S. Optic pathway gliomas in children: Clinical characteristics, treatment, and outcome of 95 patients in a single center over a 31‐year period. Can we avoid radiotherapy?. Pediatric Blood & Cancer. 2024;71(12). doi:10.1002/pbc.31337
BibTeX
@article{Kebudi2024,
author = {Kebudi, Rejin and Yildirim, Ulku Miray and İribaş, Ayça and Tuncer, Samuray},
title = {Optic pathway gliomas in children: Clinical characteristics, treatment, and outcome of 95 patients in a single center over a 31‐year period. Can we avoid radiotherapy?},
journal = {Pediatric Blood & Cancer},
year = {2024},
volume = {71},
number = {12},
doi = {10.1002/pbc.31337}
}
EUVIMED